Rick Doblin, Ph.D., is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit established in 1986 to advance evidence-based psychedelic therapy and end prohibition. MAPS incubated Lykos Therapeutics (formerly MAPS Public Benefit Corporation) which is leading drug development of MDMA-assisted therapy for PTSD.
Learn more about Psychedelic Science 2025, June 16–20 at the Colorado Convention Center in Denver, at www.psychedelicscience.org, and visit www.maps.org for information on MAPS
